Letter | Published:

Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome

  • A Correction to this article was published on 01 December 2001
  • An Erratum to this article was published on 01 January 2002

Abstract

Noonan syndrome (MIM 163950) is an autosomal dominant disorder characterized by dysmorphic facial features, proportionate short stature and heart disease (most commonly pulmonic stenosis and hypertrophic cardiomyopathy)1,2. Webbed neck, chest deformity, cryptorchidism, mental retardation and bleeding diatheses also are frequently associated with this disease. This syndrome is relatively common, with an estimated incidence of 1 in 1,000–2,500 live births. It has been mapped to a 5-cM region (N-SH2) on chromosome 12q24.1, and genetic heterogeneity has also been documented3,4,5,6. Here we show that missense mutations in PTPN11 (MIM 176876)—a gene encoding the nonreceptor protein tyrosine phosphatase SHP-2, which contains two Src homology 2 (SH2) domains—cause Noonan syndrome and account for more than 50% of the cases that we examined. All PTPN11 missense mutations cluster in interacting portions of the amino N-SH2 domain and the phosphotyrosine phosphatase domains, which are involved in switching the protein between its inactive and active conformations. An energetics-based structural analysis of two N-SH2 mutants indicates that in these mutants there may be a significant shift of the equilibrium favoring the active conformation. This implies that they are gain-of-function changes and that the pathogenesis of Noonan syndrome arises from excessive SHP-2 activity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. 1

    Noonan, J.A. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am. J. Dis. Child. 116, 373–380 (1968).

  2. 2

    Allanson, J.E. Noonan syndrome. J. Med. Genet. 24, 9–13 (1987).

  3. 3

    Jamieson, C.R. et al. Mapping a gene for Noonan syndrome to the long arm of chromosome 12. Nature Genet. 8, 357–360 (1994).

  4. 4

    Brady, A.F. et al. Further delineation of the critical region for Noonan syndrome on the long arm of chromosome 12. Eur. J. Hum. Genet. 5, 336–337 (1997).

  5. 5

    Legius, E., Schollen, E., Matthijs, G. & Fryns, J.P. Fine mapping of Noonan/cardio-facio cutaneous syndrome in a large family. Eur. J. Hum. Genet. 6, 32–37 (1998).

  6. 6

    van Der Burgt, I. & Brunner, H. Genetic heterogeneity in Noonan syndrome: evidence for an autosomal recessive form. Am. J. Med. Genet. 94, 46–51 (2000).

  7. 7

    Dechert, U. et al. Protein-tyrosine phosphatase SH-PTP2 (PTPN11) is localized to 12q24.1-24.3. Hum. Genet. 96, 609–615 (1995).

  8. 8

    Feng, G.-S. Shp-2 tyrosine phosphatase: signaling one cell or many. Exp. Cell Res. 253, 47–54 (1999).

  9. 9

    Chen, B. et al. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nature Genet. 24, 296–299 (2000).

  10. 10

    Lee, C.H. et al. Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase. Structure 2, 423–438 (1994).

  11. 11

    Eck, M.J., Pluskey, S., Trub, T., Harrison, S.C. & Shoelson, S.E. Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Nature 379, 277–280 (1996).

  12. 12

    Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M.J. & Shoelson, S.E. Crystal structure of the tyrosine phosphatase SHP-2. Cell 92, 441–450 (1998).

  13. 13

    Allen, M.P. & Tildesley . Computer Simulation of Liquids (Clarendon, Oxford, 1987).

  14. 14

    Noguti, T. & Go, N. Efficient Monte Carlo method for simulation of fluctuating conformations of native proteins. Biopolymers 24, 527–546 (1985).

  15. 15

    O'Reilly, A.M., Pluskey, S., Shoelson, S.E. & Neel, B.G. Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps. Mol. Cell. Biol. 20, 299–311 (2000).

  16. 16

    Arrandale, J.M. et al. Insulin signaling in mice expressing reduced levels of Syp. J. Biol. Chem. 271, 21353–21358 (1996).

  17. 17

    Saxton, T.M. et al. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J. 16, 2352–2364 (1997).

  18. 18

    Tang, T.L., Freeman, R.M. Jr, O'Reilly, A.M., Neel, B.G. & Sokol, S.Y. The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early Xenopus development. Cell 80, 473–483 (1995).

  19. 19

    Perkins, L.A., Johnson, M.R., Melnick, M.B. & Perrimon, N. The nonreceptor protein tyrosine phosphatase corkscrew functions in multiple receptor tyrosine kinase pathways in Drosophila. Dev. Biol. 180, 63–81 (1996).

  20. 20

    Qu, C.K. et al. Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells. Mol. Cell. Biol. 18, 6075–6082 (1998).

  21. 21

    Saxton, T.M. et al. The SH2 tyrosine phosphatase shp2 is required for mammalian limb development. Nature Genet. 24, 420–423 (2000).

  22. 22

    Stein-Gerlach, M., Wallasch, C. & Ullrich, A. SHP-2, SH2-containing protein tyrosine phosphatase-2. Int. J. Biochem. Cell. Biol. 30, 559–566 (1998).

  23. 23

    Tamir, I., Dal Porto, J.M. & Cambier, J.C. Cytoplasmic protein tyrosine phosphatase SHP-1 and SHP-2: regulators of B cell signal transduction. Curr. Opin. Immunol. 12, 307–315 (2000).

  24. 24

    Shi, Z.Q., Lu, W. & Feng, G.S. The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases. J. Biol. Chem. 273, 4904–4908 (1998).

  25. 25

    You, M., Yu, D.H. & Feng, G.S. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell. Biol. 19, 2416–2424 (1999).

  26. 26

    Maroun, C.R., Naujokas, M.A., Holgado-Madruga, M., Wong, A.J. & Park, M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 20, 8513–8525 (2000).

  27. 27

    You, M., Flick, L.M., Yu, D. & Feng, G.S. Modulation of the nuclear factor κB pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor. J. Exp. Med. 193, 101–110 (2001).

  28. 28

    Brooks, B.R. et al. CHARMM — a program for macromolecular energy, minimization and dynamics calculations. J. Comput. Chem. 4, 165–175 (1983).

  29. 29

    MacKerell, A.D. et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102, 3586–3616 (1998).

  30. 30

    Hassan, S.A., Mehler, E.L. & Weinstein, H. in Lecture Notes Series in Computational Science (ed. Schlick, T.) (Springer, New York, in press).

  31. 31

    Shenkin, P.S. & McDonald, D.Q. Cluster analysis of molecular conformations. J. Comput. Chem. 15, 899–916 (1994).

  32. 32

    Hassan, S.A., Guarnieri, F. & Mehler, E.L. A general treatment of solvent effects based on screened Coulomb potentials. J. Phys. Chem. B 104, 6478–6489 (2000).

Download references

Acknowledgements

We thank the individuals with Noonan syndrome and their families who participated in this study, the physicians who referred the subjects, X. Song for technical assistance, H. Weinstein for insightful suggestions about the structural analysis, S. Hassan for providing algorithms and programs to carry out the Montre Carlo calculations and for discussions and G. Diaz and Y. Ioannou for reading the manuscript. This work was supported in part by grants from the NIH (to B.D.G., E.L.M. and R.K.) and from the Human Genetics Program at the Albert Einstein College of Medicine (to R.K.).

Author information

Correspondence to Marco Tartaglia.

Rights and permissions

Reprints and Permissions

About this article

Further reading

Figure 1: PTPN11 organization and SHP-2 domain structure.
Figure 2: PTPN11 mutations in Noonan syndrome.
Figure 3: Structure of SHP-2 with mutated residues.
Figure 4: Plots of root mean-square deviation (RMSD) against energy for the wildtype and two mutant N-SH2 segments of SHP-2.